Bayers, Dual

Bayer's Dual Milestones: Sunharbo Launch and Roundup Settlement Approval

Published on 11/22/2026 at 19:01 | Editorial boerse-global.de
Bayer began US orders for Sunharbo, its newly approved stroke-prevention tablet, as a Missouri court granted final approval to a Roundup settlement worth up to $7.25 billion.
Bayers, Dual, Milestones, Sunharbo, Launch, Roundup, Settlement, Approval, Bayer, Missouri Illustration mit AI erstellt.

Bayer's US commercial machine has begun taking orders for Sunharbo, the newly approved stroke-prevention tablet, just as a Missouri court handed the German group a binding ceiling on its long-running Roundup litigation. The twin developments landed on the same Friday, giving investors two distinct catalysts to weigh.

The medicine, whose active ingredient is asundexian, is being offered in 50 mg tablets to hospitals, health systems and pharmacies across the United States. The FDA cleared it to reduce the risk of recurrent strokes, and Bayer is calling it the world's first approved factor XIa inhibitor. Shares of the Leverkusen-based company added 1.2% on the day the distribution news broke, closing at €55.16.

A Court-Backed Ceiling on Glyphosate Claims

On the legal front, the Missouri ruling grants final approval to Bayer's US class settlement over Roundup, a package worth up to $7.25 billion. Monsanto is to pay out that sum over as many as 21 years, inclusive of amounts already disbursed. The settlement is designed to resolve both pending and potential future claims alleging non-Hodgkin lymphoma. Appeals against the approval remain possible.

Should investors sell immediately? Or is it worth buying Bayer?

Bayer framed the decision as a milestone in its strategy to contain existing and prospective litigation. In after-hours Tradegate trading on Friday, the stock initially climbed 3% following the news.

Brokers Move in Tandem

Two brokerage houses revised their price targets in quick succession, though they diverged on the rating. Berenberg on Wednesday lifted its target to €62.00 from €53.50 while keeping a "Hold" stance. Kepler Cheuvreux followed on Thursday, raising its target to €68 from €59 and reaffirming its buy recommendation.

Berenberg pointed to momentum in the pharmaceuticals division and to potential proceeds from an initial public offering of Monsanto toward the end of the decade.

Revenue Base

Bayer reported third-quarter 2026 revenue of €10.05 billion on November 3, up from €9.66 billion in the same period a year earlier.

Ad

Bayer Stock: New Analysis - 22 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYERS | boerse | 70544753 |